Novel anthranilic amides and the use thereof
AssigneesThe Administrators of the Tulane Educational Fund, Duquesne University of the Holy Ghost
InventorsSuravi CHAKRABARTY, Patrick T. FLAHERTY, Darlene MONLISH, Jane E. CAVANAUGH, Matthew E. BUROW, Steven ELLIOTT, Van T. HOANG
Life of this patent
Estimating the term…
Abstract
Disclosed are anthranilic amide derivatives having the formula: Compositions are disclosed that include the anthranilic amide derivatives and the use of the anthranilic amide derivatives for the manufacture of a medicament. Further disclosed are methods of inhibiting or treating cancer, inhibiting or reversing an epithelial to mesenchymal cellular transition, and/or inhibiting MEK1/2 and/or MEK 5 enzymatic activity in a subject by administering to the subject an effective amount of a disclosed anthranilic amide derivative.
Claims32
A compound, having the formula:
- wherein R1 independently is:
- a primary or tertiary amine group, a OR11 group, or an amino acid group, and wherein the R11 independently is a hydrogen, an alkyl, an alkene, or an alkyne group;
- wherein R3, R5, R6, R9, and R10 are each independently a hydrogen, an alkyl, an alkene, an alkyne, a halogen, an alkoxy group with or without one or more carbon-carbon double or triple bonds, a cyano group, or a nitrile group;
- wherein R2 and/or R4 is/are independently a halogen group, and, when not a halogen group, R2 or R4 is a hydrogen group, and, when R1 is a primary amine group or a OR11 group, R2 or R4, but not both, is a halogen group;
- and
- wherein R7 and R8 are each independently a halogen group.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.